 |
|
 -Acetylenic GABA in Tardive Dyskinesia
Daniel E. Casey, MD;
Jes Gerlach, MD;
Gerhard Magelund, MD;
Torben Rosted Christensen, MD
Arch Gen Psychiatry. 1980;37(12):1376-1379.
Abstract
• Brain  -aminobutyric acid (GABA) has been proposed to play a role in the modulation of extrapyramidal motor function. The effects of increasing brain GABA with -acetylenic GABA (GAG), a drug that inhibits GABA transaminase, were evaluated in ten patients with stable tardive dyskinesia during a blind placebo-controlled trial. Drug effects during active treatment and two placebo periods were evaluated by scoring randomly sequenced videotapes of tardive dyskinesia and parkinsonian symptoms recorded weekly during a standardized examination. Tardive dyskinesia was significantly reduced, and preexisting parkinsonism increased slightly. The largest decrease in tardive dyskinesia symptoms occurred in patients receiving higher neuroleptic doses, suggesting an interaction between GABA and dopamine. Prolactin values increased but growth hormone values were unchanged. Psychiatric symptoms were also unchanged during GAG treatment.
Author Affiliations
From Departments H (Drs Casey, Gerlach, and Christensen), and E (Dr Magelund), Set Hans Hospital, Roskilde, Denmark, and the Departments of Medical Research, Psychiatry, and Neurology (Dr Casey), Veterans Administration Medical Center and University of Oregon Health Sciences Center, Portland.
Footnotes
Accepted for publication Jan 30, 1980.
Reprint requests to Department of Psychiatry, Veterans Administration Medical Center, Sam Jackson Park, Portland, OR 97201 (Dr Casey).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
New Models of Frontal-Subcortical Skeletomotor Circuit Pathology in Tardive Dyskinesia
Marchand and Dilda
Neuroscientist 2006;12:186-198.
ABSTRACT
Clinical assessment of the extrapyramidal side effects of antipsychotic drugs
Barnes
J Psychopharmacol 1992;6:214-221.
Brain {gamma}-Aminobutyric Acid Abnormality in Tardive Dyskinesia: Reduction in Cerebrospinal Fluid GABA Levels and Therapeutic Response to GABA Agonist Treatment
Thaker et al.
Arch Gen Psychiatry 1987;44:522-529.
ABSTRACT
The Effect of Buspirone on Prolactin and Growth Hormone Secretion in Man
Meltzer et al.
Arch Gen Psychiatry 1983;40:1099-1102.
ABSTRACT
The Effect of Tetrahydroisoxazolopyridinol (THIP) in Tardive Dyskinesia: A New {beta}-Aminobutyric Acid Agonist
Korsgaard et al.
Arch Gen Psychiatry 1982;39:1017-1021.
ABSTRACT
Therapeutic Strategies Against Tardive Dyskinesia: Two Decades of Experience
Jeste and Jed Wyatt
Arch Gen Psychiatry 1982;39:803-816.
ABSTRACT
CSF Levels of {gamma}-Aminobutyric Acid in Schizophrenia: Low Values in Recently Ill Patients
van Kammen et al.
Arch Gen Psychiatry 1982;39:91-97.
ABSTRACT
Effect of Des-Tyrosine-{gamma}-Endorphin in Tardive Dyskinesia
Casey et al.
Arch Gen Psychiatry 1981;38:158-160.
ABSTRACT
|
